Who Is Buying Moderna? Hedge Fund Activity in 2026

Moderna, the mRNA pioneer that became a household name during the COVID-19 pandemic, is now navigating one of the most consequential chapters in its corporate history. Having built a massive cash war chest from COVID vaccine sales, the company is aggressively reinvesting into its next-generation pipeline — including RSV vaccines, individualized cancer therapies, and combination respiratory shots. The stock has been volatile, oscillating between pandemic-era hype and post-pandemic skepticism, but the latest institutional filings suggest that smart money is increasingly placing bets on Moderna's future beyond COVID.

The most recent 13F filings paint a decidedly bullish picture: 7 out of 15 tracked funds are buying or increasing their Moderna positions, with three entirely new positions opened during the quarter. This is a significant shift in institutional sentiment for a stock that many had written off.

Moderna Institutional Snapshot

A 7-to-4 buy-sell ratio represents a moderately bullish tilt. What makes this particularly noteworthy is the three brand-new positions — Renaissance Technologies, Coatue Management, and Appaloosa Management all initiated fresh stakes. When multiple sophisticated quant and fundamental shops simultaneously decide to enter a name, it's worth paying attention.

Who's Buying Moderna?

The buyer list is led by heavyweight institutional managers making substantial increases to existing positions, plus three notable new entrants:

Vanguard Group — $2B (Increased) Vanguard continues to build its already massive Moderna position, now valued at $2 billion. As the world's largest index fund manager, Vanguard's increase reflects both passive inflows and the stock's growing weight in healthcare indices. The sheer size of this position underscores Moderna's importance in institutional portfolios.

Fidelity Investments — $1.4B (Increased) Fidelity's active managers have been steadily adding to their Moderna exposure, pushing the position to $1.4 billion. Fidelity's healthcare-focused funds have deep expertise in biotech pipeline analysis, and their continued accumulation suggests confidence in Moderna's clinical programs beyond the base COVID franchise.

D.E. Shaw — $255M (Increased) The quantitative powerhouse increased its position to $255 million, a substantial commitment for a quant-driven fund. D.E. Shaw's algorithms likely detected favorable risk-reward characteristics in MRNA's current valuation relative to its pipeline potential, and the fund has been steadily building this position over multiple quarters.

Citadel Advisors — $28.5M (Increased) Ken Griffin's multi-strategy giant bumped its Moderna exposure to $28.5 million. While modest relative to Citadel's overall book, any increase from one of the world's most sophisticated trading operations is a signal that the firm sees near-term upside potential in the stock.

Renaissance Technologies — $28M (NEW POSITION) Jim Simons' legendary quant fund opened a brand-new $28 million position in Moderna. Renaissance is famously secretive and algorithmic — they don't make moves based on gut feelings. A new position from Renaissance suggests their models have identified a statistically favorable setup in MRNA, potentially driven by mean-reversion signals or pipeline catalyst timing.

Coatue Management — $9.8M (NEW POSITION) Philippe Laffont's tech-and-biotech-focused fund initiated a $9.8 million position. Coatue has a strong track record in identifying transformative platform technologies, and their entry into Moderna signals conviction that the mRNA platform has applications far beyond respiratory vaccines — potentially in oncology and rare diseases.

Appaloosa Management — $590.9K (NEW POSITION) David Tepper's Appaloosa opened a small but noteworthy starter position at $590.9K. Tepper is known for making bold, concentrated bets, and this looks like a toe-in-the-water move that could be scaled significantly if the thesis plays out. Appaloosa typically builds positions over multiple quarters.

Who's Selling Moderna?

Four institutional investors reduced their Moderna exposure in the latest filings:

State Street — $805.2M (Decreased) State Street trimmed its position but still holds over $805 million — a massive stake by any measure. The decrease likely reflects rebalancing rather than a bearish call, as State Street's index-tracking mandates require periodic adjustments based on market cap changes and fund flows.

Two Sigma — $361.2M (Decreased) The quantitative trading firm reduced its position to $361.2 million. Two Sigma's models are highly responsive to short-term price momentum and volatility metrics, so this reduction may reflect tactical repositioning rather than a fundamental view change. The fund still maintains a very significant position.

Millennium Management — $19.9M (Decreased) Israel Englander's pod-based hedge fund trimmed to $19.9 million. Millennium's individual portfolio managers operate with tight risk limits, and position reductions often reflect risk management rather than directional views. The fact that they maintained the position at all is somewhat constructive.

Bridgewater Associates — $746.9K (Decreased) Ray Dalio's macro fund reduced its already small Moderna position to under $1 million. Bridgewater's approach is macro-driven, and this minimal allocation suggests healthcare biotech isn't a core theme in their current macro framework — though the fact that they haven't exited entirely is notable.

Notable Moves

The standout story this quarter is the three simultaneous new positions from Renaissance Technologies, Coatue Management, and Appaloosa Management. It's relatively rare to see three sophisticated funds with very different investment approaches all initiate positions in the same quarter. Renaissance brings quantitative validation, Coatue brings deep platform-technology conviction, and Appaloosa brings value-oriented contrarian thinking. This convergence of new interest from diverse investment philosophies is one of the strongest bullish signals we've tracked.

Also noteworthy: D.E. Shaw's continued accumulation at $255 million represents one of the larger quant-fund positions in Moderna. When two major quant shops (D.E. Shaw increasing, Renaissance entering) are both moving in the same direction, it adds significant weight to the bullish case.

On the selling side, the reductions are relatively modest and appear more tactical than conviction-driven. State Street and Two Sigma still hold enormous positions, and the selling looks more like portfolio maintenance than a rush for the exits.

What This Signals

The institutional landscape around Moderna is tilting clearly bullish. A 7-to-4 buy-sell ratio with three new positions paints a picture of growing smart-money confidence. Here's what investors should consider:

The mRNA platform is being re-rated. Moderna's pipeline extends far beyond COVID boosters. The company's RSV vaccine, flu-COVID combination shots, and personalized cancer vaccines (in partnership with Merck) represent a diversified portfolio of potential blockbusters. Institutional buyers appear to be positioning ahead of key clinical readouts.

Quant funds see favorable dynamics. Both Renaissance (new) and D.E. Shaw (increasing) are quantitative operations that rely on data-driven signals. Their simultaneous bullishness suggests that MRNA's price action, volatility profile, and fundamental metrics are flashing buy signals across multiple model types.

Selling is shallow, not panicked. The four sellers all maintained significant positions. This isn't a stampede for the exits — it's normal portfolio management. State Street alone still holds over $805 million, dwarfing most of the selling activity.

The contrarian case is building. Moderna has been one of the most heavily shorted and most debated stocks in biotech. When sophisticated funds start opening new positions in a controversial name, it often precedes a sentiment shift in the broader market.

Risk factors remain. Moderna's cash burn rate is significant as it funds its pipeline expansion. The company needs to demonstrate that its mRNA platform can produce commercially successful products beyond COVID to justify its current valuation. Pipeline setbacks could quickly reverse institutional sentiment.

For individual investors, the message from 13F filings is relatively clear: the smartest money in the room is betting that Moderna's best days aren't behind it — they're ahead. The combination of new position openings and continued accumulation by existing holders suggests institutional confidence in the mRNA platform's long-term potential.

---

Track MRNA institutional activity and portfolio changes in real time at app.freenance.io/smart-money/ticker/MRNA.

Related Articles

• Who Is Buying Gilead Sciences? Hedge Fund Activity in 2026
• Who Is Buying Regeneron? Hedge Fund Activity in 2026
• Who Is Buying Vertex Pharmaceuticals? Hedge Fund Activity in 2026

FAQ

Why are funds revisiting Moderna after the post-COVID drawdown?

The bullish case has shifted from COVID boosters to the broader mRNA platform — RSV vaccines, flu-COVID combinations, and personalized cancer vaccines partnered with Merck. Institutional buyers appear to be positioning ahead of pipeline catalysts rather than reacting to legacy COVID revenue trends.

What's notable about Renaissance, Coatue, and Appaloosa all opening new positions?

Three sophisticated funds with very different methodologies — quantitative, platform-technology growth, and contrarian value — initiating in the same quarter is statistically unusual. That convergence across investment philosophies is one of the stronger signals visible in the 13F data, though it doesn't guarantee outcomes.

How significant is Moderna's oncology pipeline for the investment thesis?

The Merck-partnered individualized cancer vaccine (mRNA-4157) is widely seen as the highest-value asset beyond respiratory infectious disease. If Phase 3 melanoma data reads out positively, it would validate mRNA as an oncology platform — a re-rating event that several institutional buyers appear to be underwriting.

Is the selling from State Street and Two Sigma a concern?

The reductions look more tactical than conviction-driven. State Street still holds over $805 million and Two Sigma over $361 million, so neither is exiting — the trims read as portfolio maintenance, index rebalancing, and short-horizon quant repositioning rather than a fundamental view change.

What are the main risks institutional buyers are absorbing?

Moderna burns substantial cash funding pipeline expansion, and the platform still needs commercial wins beyond COVID to justify current valuation. Clinical setbacks, regulatory delays, or competitive mRNA programs could quickly reverse the improving institutional sentiment captured in these filings.